Lantheus Holdings, Inc. (LNTH) Spending and interest coverage
- R&D / revenue · 12 months: Value 11.12%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.02%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 11.12% | Research and development expense / revenue. Period ending 2026-06-30. $173.09M ÷ $1.56B × 100 ≈ 11.12% |
| Stock-based compensation / revenue · 12 months | 5.02% | Share-based compensation / revenue. Period ending 2026-06-30. $78.09M ÷ $1.56B × 100 ≈ 5.02% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 173.09M USD | Research and Development Expense |
| Revenue | 1.56B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 78.09M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 302.34M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $173.09M | $1.56B | $78.09M | $302.34M | (m) | 11.12% | 5.02% | (m) | (m) |
| 2026-03-31 | $180.37M | $1.55B | $80.41M | $290.09M | (m) | 11.67% | 5.20% | (m) | (m) |
| 2025-12-31 | $177.31M | $1.54B | $85.56M | $310.83M | (m) | 11.50% | 5.55% | (m) | (m) |
| 2025-09-30 | $165.15M | $1.53B | $90.18M | $347.52M | (m) | 10.82% | 5.91% | (m) | (m) |
| 2025-06-30 | $141.28M | $1.52B | $86.05M | $437.65M | (m) | 9.29% | 5.66% | (m) | (m) |
| 2025-03-31 | $156.39M | $1.54B | $82.21M | $452.41M | (m) | 10.18% | 5.35% | (m) | (m) |
| 2024-12-31 | $168.10M | $1.53B | $76.39M | $456.98M | (m) | 10.96% | 4.98% | (m) | (m) |
| 2024-09-30 | $149.60M | $1.50B | $68.40M | $480.59M | (m) | 9.99% | 4.57% | (m) | (m) |
| 2024-06-30 | $139.90M | $1.44B | $62.01M | $459.21M | (m) | 9.73% | 4.31% | (m) | (m) |
| 2024-03-31 | $95.20M | $1.37B | $56.22M | $480.62M | $19.89M | 6.97% | 4.12% | 24.17× | Reported |
| 2023-12-31 | $77.71M | $1.30B | $50.51M | $364.64M | $20.02M | 5.99% | 3.90% | 18.21× | Reported |
| 2023-09-30 | $333.11M | $1.21B | $44.46M | $55.48M | $17.56M | 27.63% | 3.69% | 3.16× | Reported |
| 2023-06-30 | $331.18M | $1.12B | $38.59M | $28.86M | $14.13M | 29.44% | 3.43% | 2.04× | Reported |
| 2023-03-31 | $330.01M | $1.03B | $33.31M | $-32.07M | $10.67M | 32.13% | 3.24% | -3.01× | Reported |
| 2022-12-31 | $311.68M | $935.06M | $29.26M | $36.20M | $7.18M | 33.33% | 3.13% | 5.04× | Reported |
| 2022-09-30 | $50.75M | $801.46M | $25.30M | $172.53M | $6.13M | 6.33% | 3.16% | 28.14× | Reported |
| 2022-06-30 | $49.48M | $664.24M | $21.06M | $72.46M | $6.08M | 7.45% | 3.17% | 11.93× | Reported |
| 2022-03-31 | $46.81M | $541.58M | $18.24M | $-17.52M | $6.54M | 8.64% | 3.37% | -2.68× | Reported |
| 2021-12-31 | $44.97M | $425.21M | $15.93M | $-60.83M | $7.75M | 10.58% | 3.75% | -7.85× | Reported |
| 2021-09-30 | $46.31M | $389.80M | $15.39M | $-26.02M | $9.04M | 11.88% | 3.95% | -2.88× | Reported |
| 2021-06-30 | $46.74M | $376.27M | $15.52M | $-16.94M | $10.27M | 12.42% | 4.12% | -1.65× | Reported |
| 2021-03-31 | $39.10M | $341.21M | $14.32M | $4.30M | $10.25M | 11.46% | 4.20% | 0.42× | Reported |
| 2020-12-31 | $32.79M | $339.41M | $14.07M | $-4.20M | $9.48M | 9.66% | 4.15% | -0.44× | Reported |
| 2020-09-30 | $24.58M | $334.60M | $13.44M | $8.77M | $8.79M | 7.35% | 4.02% | 1.00× | Reported |
| 2020-06-30 | $17.76M | $331.84M | $12.87M | $22.54M | $8.34M | 5.35% | 3.88% | 2.70× | Reported |
| 2020-03-31 | $19.14M | $351.53M | $12.85M | $42.62M | $10.97M | 5.44% | 3.65% | 3.88× | Reported |
| 2019-12-31 | $20.02M | $347.34M | $12.49M | $51.66M | $13.62M | 5.76% | 3.60% | 3.79× | Reported |
| 2019-09-30 | $20.14M | $344.26M | $11.80M | $56.17M | $16.10M | 5.85% | 3.43% | 3.49× | Reported |
| 2019-06-30 | $19.59M | $347.39M | $10.78M | $64.13M | $18.19M | 5.64% | 3.10% | 3.53× | Reported |
| 2019-03-31 | $18.01M | $347.25M | $9.64M | $65.52M | $17.95M | 5.19% | 2.78% | 3.65× | Reported |
| 2018-12-31 | $17.07M | $343.37M | $8.72M | $64.49M | $17.41M | 4.97% | 2.54% | 3.71× | Reported |
| 2018-09-30 | $16.50M | $338.34M | $8.58M | $56.75M | $17.06M | 4.88% | 2.54% | 3.33× | Reported |
| 2018-06-30 | $15.73M | $329.38M | $7.83M | $53.09M | $17.05M | 4.78% | 2.38% | 3.11× | Reported |
| 2018-03-31 | $16.76M | $332.65M | $6.78M | $55.06M | $17.04M | 5.04% | 2.04% | 3.23× | Reported |
| 2017-12-31 | $18.13M | $331.38M | $5.93M | $51.85M | $18.41M | 5.47% | 1.79% | 2.82× | Reported |
| 2017-09-30 | $17.86M | $324.49M | $4.42M | $54.79M | $19.97M | 5.50% | 1.36% | 2.74× | Reported |
| 2017-06-30 | $17.15M | $317.61M | $3.64M | $54.56M | $22.32M | 5.40% | 1.15% | 2.44× | Reported |
| 2017-03-31 | $14.52M | $306.74M | $3.06M | $50.84M | $25.01M | 4.73% | 1.00% | 2.03× | Reported |
| 2016-12-31 | $12.20M | $301.85M | $2.52M | $56.59M | $26.62M | 4.04% | 0.84% | 2.13× | Reported |
| 2016-09-30 | $11.56M | $298.70M | $2.35M | $56.84M | $27.90M | 3.87% | 0.79% | 2.04× | Reported |
| 2016-06-30 | $11.17M | $299.76M | $2.06M | $57.65M | (m) | 3.73% | 0.69% | (m) | (m) |
| 2016-03-31 | $11.20M | $295.11M | $2.13M | $48.83M | (m) | 3.79% | 0.72% | (m) | (m) |
| 2015-12-31 | $14.36M | $293.46M | $2.00M | $42.53M | $38.72M | 4.89% | 0.68% | 1.10× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $303.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $13.67M | $301.60M | $1.03M | $39.42M | $42.29M | 4.53% | 0.34% | 0.93× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $30.46M | $283.67M | $578.00K | $-18.89M | $42.91M | 10.74% | 0.20% | -0.44× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |